Literature DB >> 31930750

Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications.

Helen L Wu1,2, Whitney C Weber1,2, Christine Shriver-Munsch2, Tonya Swanson2, Mina Northrup1,2, Heidi Price2, Kimberly Armantrout2, Mitchell Robertson-LeVay2, Jason S Reed1,2, Katherine B Bateman1,2, Eisa Mahyari2, Archana Thomas2,3, Stephanie L Junell4, Theodore R Hobbs2, Lauren D Martin2, Rhonda MacAllister2, Benjamin N Bimber2, Mark K Slifka2,3, Alfred W Legasse2, Cassandra Moats2, Michael K Axthelm2, Jeremy Smedley2, Anne D Lewis2, Lois Colgin2, Gabrielle Meyers5, Richard T Maziarz5, Benjamin J Burwitz1,2, Jeffrey J Stanton2, Jonah B Sacha1,2.   

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) and xenotransplantation are accompanied by viral reactivations and virus-associated complications resulting from immune deficiency. Here, in a Mauritian cynomolgus macaque model of fully MHC-matched allogeneic HSCT, we report reactivations of cynomolgus polyomavirus, lymphocryptovirus, and cytomegalovirus, macaque viruses analogous to HSCT-associated human counterparts BK virus, Epstein-Barr virus, and human cytomegalovirus. Viral replication in recipient macaques resulted in characteristic disease manifestations observed in HSCT patients, such as polyomavirus-associated hemorrhagic cystitis and tubulointerstitial nephritis or lymphocryptovirus-associated post-transplant lymphoproliferative disorder. However, in most cases, the reconstituted immune system, alone or in combination with short-term pharmacological intervention, exerted control over viral replication, suggesting engraftment of functional donor-derived immunity. Indeed, the donor-derived reconstituted immune systems of two long-term engrafted HSCT recipient macaques responded to live attenuated yellow fever 17D vaccine (YFV 17D) indistinguishably from untransplanted controls, mounting 17D-targeted neutralizing antibody responses and clearing YFV 17D within 14 days. Together, these data demonstrate that this macaque model of allogeneic HSCT recapitulates clinical situations of opportunistic viral infections in transplant patients and provides a pre-clinical model to test novel prophylactic and therapeutic modalities.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Mauritian cynomolgus macaques; cytomegalovirus; hematopoietic stem cell transplantation; lymphocryptovirus; non-human primates; opportunistic infections; polyomavirus; transplant complications; yellow fever virus

Year:  2020        PMID: 31930750      PMCID: PMC7354885          DOI: 10.1111/xen.12578

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  100 in total

1.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

2.  Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.

Authors:  A Gratwohl; R Brand; F Frassoni; V Rocha; D Niederwieser; P Reusser; H Einsele; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

3.  Presence of antibody to Cyno-EBV in domestically bred cynomolgus monkeys (Macaca fascicularis).

Authors:  K Fujimoto; S Honjo
Journal:  J Med Primatol       Date:  1991       Impact factor: 0.667

4.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Catherine M Bollard; Adam M Mendizabal; Elizabeth J Shpall; Paul Szabolcs; Joseph H Antin; Neena Kapoor; Sung-Yun Pai; Scott D Rowley; Partow Kebriaei; Bimalangshu R Dey; Bambi J Grilley; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

5.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

6.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 7.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

8.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Nonhuman primate infections after organ transplantation.

Authors:  Silke V Haustein; Amanda J Kolterman; Jeffrey J Sundblad; John H Fechner; Stuart J Knechtle
Journal:  ILAR J       Date:  2008

10.  Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.

Authors:  Andreas Moosmann; Iris Bigalke; Johanna Tischer; Leah Schirrmann; Julitta Kasten; Stefanie Tippmer; Marina Leeping; Dusan Prevalsek; Gundula Jaeger; Georg Ledderose; Josef Mautner; Wolfgang Hammerschmidt; Dolores J Schendel; Hans-Jochem Kolb
Journal:  Blood       Date:  2010-01-26       Impact factor: 22.113

View more
  1 in total

1.  Terumo spectra optia leukapheresis of cynomolgus macaques for hematopoietic stem cell and T cell collection.

Authors:  Helen L Wu; Justin M Greene; Tonya Swanson; Christine Shriver-Munsch; Kimberly Armantrout; Whitney C Weber; Katherine B Bateman; Nicholas M Maier; Mina Northrup; Alfred W Legasse; Cassandra Moats; Michael K Axthelm; Jeremy Smedley; Richard T Maziarz; Lauren Drew Martin; Theodore Hobbs; Benjamin J Burwitz; Jonah B Sacha
Journal:  J Clin Apher       Date:  2020-09-17       Impact factor: 2.821

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.